{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002590","form_type":"8-K/A","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.887499+00:00","generated_at":"2026-05-27T04:03:46.770047+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiromic BioPharma issues $1M 25% senior secured convertible note; corrects prior debt total to $14.2M","bullets":["Issued $1M 25% senior secured convertible promissory note to accredited investor, maturing Jan 28, 2026.","Note convertible into common stock at 90% of 5-day VWAP starting Feb 28, 2025; beneficial ownership cap of 19.99%.","Note secured by all fixtures, equipment, and intellectual property of the Company.","Holder now holds aggregate principal of $14.2M across eight promissory notes plus preferred stock.","8-K/A corrects error: originally reported combined debt as $13.2M instead of $14.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002590","json":"https://secwatch.observer/filing/0001437749-25-002590.json","markdown":"https://secwatch.observer/filing/0001437749-25-002590.md","text":"https://secwatch.observer/filing/0001437749-25-002590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000143774925002590/0001437749-25-002590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000143774925002590/krbp20250203_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:03:46.770047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0103a508b56747b7b3df410ae1289d35f8d311ed","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $1,000,000 with an accredited investor at 25% per annum maturing January 28, 2026.","evidence_excerpt":"On January 28, 2025, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor (the “Holder”). The Note has a principal amount of $1,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on January 28, 2026 (the “Maturity Date”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000143774925002590/0001437749-25-002590-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$1,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"January 28, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}